Abstract-C-C chemokine receptor 7 (CCR7) and its chemoattractant agonist CCL21 promote cell migration and expression of pro-inflammatory proteins in an atherogenic environment. Since A 2A adenosine receptor activation reduces migration and inflammatory effects, we examined its effect on CCR7 expression and migration. CCR7 protein expression decreased by about a third in macrophages treated with A 2A receptor agonist CGS 21680 (p=0.028, n=7) and was reversed with antagonist, although mRNA levels increased twofold (p=0.001, n=3). Furthermore, macrophages treated with CGS 21680 showed a significant decrease in migration (p=0.0311, n=7). These results suggest that A 2A adenosine receptor activation not only modulates CCR7 expression in both normal and inflammatory environments but also regulates macrophage migration to CCR7-specific chemoattractants.
INTRODUCTION
Atherogenesis occurs when arterial injury leads to a persistent inflammatory response-inflammatory cells respond and migrate to the area, macrophages take up oxidized low-density lipoprotein and, in the process, become foam cells, undergo apoptosis, and accumulate around the lesion, forming a growing plaque that undergoes ineffective repair and may calcify, becoming a complex plaque [1] [2] [3] [4] . Chemokines and their receptors play a role in atherogenesis and arterial repair by regulating the recruitment and function of pro-inflammatory and plaque-destabilizing cells [5] [6] [7] .
The purine adenosine accumulates during tissue injury or stress and, like chemokines, can modulate immune response and cellular function through its receptor subtype A 2A [8] [9] [10] [11] . A 2A adenosine receptor activation suppresses inflammation by regulating cytokine production and prevents atherogenesis by suppressing cell migration and reducing foam cell formation through reverse cholesterol transport [12] [13] [14] [15] [16] [17] . The A2A adenosine receptor also modulates chemokine receptor levels; in particular, it downregulates C-C chemokine ABBREVIATIONS: cAMP, Cyclic adenosine monophosphate; CCL19, C-C chemokine ligand 19; CCL21, C-C chemokine ligand 21; CCR7, C-C chemokine receptor subtype 7; CGS21680, 2-p-(2-carboxyethyl) phenethyllamino-5'-N-ethylcarboxamido-adenosine; DMSO, Dimethyl sulfoxide; Epac, Guanine nucleotide exchange factor activated by cAMP; Erk, Extracellular signal regulated kinase; FBS, Fetal bovine serum; GAPDH, Glyceraldehyde phosphate dehydrogenase; IFNγ, Interferon gamma; MAPK, Mitogen-activated protein kinase; Mek, MAP kinase kinase; p38, p38 mitogen-activated protein kinase; PCR, Polymerase chain reaction; PKA, Protein kinase A; Rac, Subfamily of Rho GTPases; RNA, Ribonucleic acid; RPMI-1640, Roswell Park Memorial Institute media; SDS-PAGE, Sodium dodecyl sulfate-polyacrylamide gel electrophoresis; SEM, Standard error mean; [18] [19] [20] . The attraction of monocytes and macrophages to CCR7's agonists could be used to prevent atherogenesis-if fewer new macrophages migrate into the atherosclerotic plaque, further arterial injury may be prevented.
We hypothesized that A2A adenosine receptor activation modulates CCR7 macrophage expression and migration. We found that while A2A adenosine receptor stimulation increased CCR7 mRNA, it decreased protein expression in both noninflammatory and inflammatory environments. As a result, chemotaxis of cells to CCR7 agonists decreased. We also examined signaling at A2A receptors for regulation of CCR7 receptors and found that, as with other functions, adenosine A2A receptors regulate CCR7 expression by a pathway dependent on PKA and MAPK.
MATERIALS AND METHODS

Materials
The selective A 2A receptor agonist CGS21680 and its antagonist ZM 241385 were purchased from Tocris Cookson (Bristol, UK). The selective CCR7 agonists CCL19 and CCL21 and the cytokine IFNγ were obtained from R&D Systems (Minneapolis, MN). Epac agonist 8-pcPT-2′-O-Me-cAMP was purchased from Axxora Diagnostics (San Diego, CA) and PKA inhibitor PKI, corresponding to amino acids 5 through 24, from Promega (Madison, WI). Rac inhibitor 553502 and p38 inhibitor SB202190 were obtained from Calbiochem (San Diego, CA), and Mek inhibitor U0126 from SigmaAldrich (St. Louis, MO).
Cell Culture
Human monocytic THP1 cells were purchased from American Type Culture Collection (Manassas, VA). Cells were grown in RPMI-1640 media supplemented with 10% FBS, 1% penicillin and streptomycin, and 1% L-glutamine (Invitrogen, Carlsbad, CA) at 37°C, 5% CO 2 . Cells were differentiated to macrophages by incubation with 25 ng/mL phorbol 12-myristate 13-acetate (Sigma-Aldrich) for 48 h.
RNA Isolation and Real-Time RT-PCR
THP1 monocytes were differentiated to macrophages (700,000 cells per milliliter), given fresh media, and treated with combinations of CGS21680 (1 μM and 100 nM) and ZM241385 (10 μM) for 4 h. For inflammatory experiments, cells were pretreated with 500 U/mL IFNγ for 12 to 16 h. For signaling experiments, cells were pretreated for 1 h with PKA inhibitor (10 μM), p38 inhibitor (10 μM), Rac inhibitor (10 μM), or Mek inhibitor (10 μM). Media were then removed, and RNA was extracted using Trizol (Invitrogen) according to the manufacturer's instructions. Of total RNA, 1.5 μg was used from each sample for firststrand, complementary deoxyribonucleic acid synthesis with random hexamer primers using an RNA PCR Core Kit (Applied Biosystems, Foster City, CA).
For quantification by real-time PCR, the following primer pairs were used: CCR7 F: 5′-TGACATGCAC TCAGCTCTTG-3 R: 5′-AGGTTTTCAGTCCCTGTGA C-3′ (60°C, 136 bp). GAPDH F: 5′-AACATCATCCCTG CCTCTAC-3′ R: 5′-CCCTCTTGCTGATGCCAAAT-3′ (58°C, 358 bp). PCR product was detected using SYBR Green and the MxPro 3005P from Agilent Technologies (Cedar Creek, TX). Gene expression was quantified to a standard curve and normalized to GAPDH.
Western Blot Analysis
Monocytes were differentiated to macrophages (1.5 million cells per milliliter), given fresh media, and treated with the appropriate cytokines, agonists, and inhibitors for 48 h. Cells were then lysed using radioimmunoprecipitation assay buffer with protease inhibitor cocktail (Sigma-Aldrich) for 30 min at 4°C, centrifuged at 10,000 rpm for 10 min, and the supernatant recovered. Of protein, 35 μg was separated by 10% SDS-PAGE and electrotransferred to nitrocellulose membranes (BioRad, Hercules, CA). Nonspecific antibody binding was blocked with Superblock T20 (Thermo, Rockford, IL) for 4 h at room temperature. The membrane was incubated with a primary antibody against CCR7 (goat polyclonal from Santa Cruz Biotechnologies, Santa Cruz, CA) overnight at 4°C and then incubated with anti-goat secondary antibody conjugated to alkaline phosphatase (Santa Cruz Biotechnologies) for 1 h at room temperature, after washing with TTBS. Protein bands were visualized using electrochemifluorescence substrate and a Storm Phosphoimager (GE Healthcare). Then, the membrane was stripped and incubated with a primary antibody against beta-actin (mouse monoclonal from Abcam, Cambridge, MA) to be used as an internal, normalizing standard. Band intensity was quantified using Kodak Molecular Imaging software (Eastman Kodak, Rochester, NY).
In Vitro Chemotaxis Cell Migration Assay
Monocytes were differentiated into macrophages, given fresh media, and pretreated with the appropriate cytokines, agonists, and antagonists for 48 h. Two hundred thousand cells were then gently lifted using rubber scrapers and Dispase (Roche, Mannheim, Germany) and added to 5-μm chamber inserts cells from the QCM Cell Migration Assay Kit (Chemicon, Temecula, CA) with fresh media containing 1% FBS, 1% penicillin-streptomycin, and 1% L-glutamine in RPMI-1640 media (Invitrogen); 300 ng/mL CCL19 or CCL21 was added to starved media in the lower chamber as a chemoattractant. Cells were then incubated for 24 h, and contents of the lower chamber were detached, stained with fluorescein, and lysed according to the manufacturer's instructions. Migration was quantified using the Victor 3 V Plate Reader (Perkin Elmer).
Statistics
Data are reported as the mean±SEM. Differences between treatment groups were analyzed with GraphPad Prism (GraphPad Software, San Diego, CA) using one-way analysis of variance followed by Tukey posttest, paired and unpaired Student's t tests. A p value of less than 0.05 was considered statistically significant.
RESULTS
A 2A Adenosine Receptor Agonist CGS21680 Increases CCR7 mRNA Expression
There was a dose-dependent increase in CCR7 message in macrophages following treatment with the adenosine A2A agonist CGS21680 (p<0.001 vs. control, n = 3), and co-treatment with the A 2A antagonist ZM241385 abrogated the increase p<0.01 vs. CGS, n=3, Fig. 1a) .
Cytokines, which are abundant in atherosclerotic lesions, may affect expression of such genes as A 2A adenosine receptor expression in THP1 cells. Indeed, IFNγ diminishes both expression and function of A 2A receptors and plays a central role in atherogenesis [13] . We therefore determined whether IFNγ altered A 2A -mediated increases in CCR7 mRNA. We were surprised to observe that, unlike other adenosine receptor functions, IFNγ did not alter adenosine A 2A -mediated increase in CCR7 message or the capacity of ZM241385 to reverse that effect (p<0.04 vs. CGS, n=3, Fig. 1b) .
A 2A Adenosine Receptor Agonist CGS21680 Decreases CCR7 Protein Expression Because A2A receptor stimulation increased mRNA for CCR7, we next determined whether A 2A adenosine receptor activation similarly regulated CCR7 protein expression. We were surprised to find that, in contrast to mRNA expression, CCR7 protein levels decreased by about a third (p<0.03 vs. control, n=7), an effect that was reversed by the antagonist (p<0.05 vs. CGS, n=7, Fig. 2a) . Pretreatment with the cytokine IFNγ also decreased CCR7 protein levels with CGS21680 treatment (p<0.04 vs.
control, n=3) and reversed with ZM241385 (p<0.03 vs. CGS, n=3, Fig. 2b ).
CGS21680 Modulates CCR7-Mediated Migration in Normal and Pro-inflammatory Environments
Prior work has indicated that adenosine A 2A receptor stimulation retards chemotactic migration to CCR7 ligands by dendritic cells, and our studies indicate . CGS21680 treatment with pro-inflammatory cytokines decreases THP1 macrophage migration to CCR7 agonists. Cells were pretreated overnight with IFNγ (500 U/mL) or TNFα (10 ng/mL) and then with CGS21680 (10 −6 M) or DMSO as a negative control for 48 h.
Cells were then lifted, added in suspension to 5-μm upper chamber inserts, and migrated to a lower chamber with a CCL19 (300 ng/mL) or b CCL21 (300 ng/mL) for 24 h. Migration was quantified using fluorescein labeling of cells. Data shown are the means±SEM of the percentages of three independent experiments with CCL19 and six with CCL21. vs. Control, * p=0.0311, ** p=0.0389, *** p=0.0196. vs. IFNγ, #p=0.0273.
that adenosine A 2A receptor stimulation diminishes CCR7 expression on THP-1 cells [18] . We therefore determined whether adenosine A 2A receptor stimulation regulates chemotaxis to CCR7 ligands by THP-1 cells in the absence or presence of inflammation. CGS21680 pretreatment reduced migration by 17% to CCL21 (p<0.03 vs. control, n=7) and by a similar amount after IFNγ pretreatment (p<0.03 vs. IFNγ, n=7, Fig. 3 ). Migration to CCL19, a ligand for CCR7, was also reduced. As with the effects on CCR7 expression, the effects of the adenosine receptor agonist were reversed by the A 2A receptor antagonist ZM241385 (p<0.008 vs. CGS, n=7, Fig. 4) .
A 2A Adenosine Receptor-Induced Changes in CCR7 Expression Are Blocked with PKA, p38, and Mek Inhibitors A 2A adenosine receptors stimulate adenylate cyclase activity and increase cellular cAMP content, which activates Epac and/or PKA, which activate signaling pathways including MAPK and p38 [21, 22] . To probe the signaling pathways involved, we used pharmacologic inhibitors of protein kinase A and erk1/2 and p38 MAP kinases and observed their effect on the capacity of adenosine A 2A receptor stimulation to alter mRNA levels for CCR7. We found inhibitors of PKA and Mek, but not a p38MAPK inhibitor or an inhibitor of rac (Fig. 5a,  b) . In contrast, p38 and rac inhibition completely blocked the effect of A 2A receptor stimulation on CCR7 protein expression (p <0.05 vs. CGS with p38 inhibition, n =4, Fig. 5c, d ).
DISCUSSION
Since A 2A adenosine receptor stimulation reduces inflammatory and atherogenic effects and CCR7 activation promotes these functions, we hypothesized that A 2A adenosine receptor activation could reduce CCR7 expression and thus modulate macrophage migration to inflamed sites or atherosclerotic plaques. Our results provide very interesting results regarding the effects of A 2A receptor ligation on CCR7 expression. We found that receptor ligation increases CCR7 mRNA by a PKA-and MEK-dependent pathway but diminishes surface expression of the protein by a p38MAPK-, rac-dependent pathway (Fig. 6) . Clearly, the resulting reduction in CCR7 chemotactic function results from the diminished receptor expression/ function. Macrophages near or within an atherosclerotic plaque are exposed to inflammatory cytokines like IFNγ, which diminish A 2A adenosine receptor expression and function and might influence their ability to regulate CCR7 levels [13, 23] . Furthermore, reverse cholesterol transport experiments demonstrate that A 2A adenosine receptor function in macrophages is altered by IFNγ [12, 15, 17, 24] . Unlike other adenosine A 2A receptor-mediated effects, the A 2A receptor-stimulated effects on CCR7 mRNA and protein expression were unaffected by IFNγ.
The contrast between adenosine receptor-stimulated increases in CCR7 mRNA and decreases in CCR7 protein expression and function were surprising. One explanation for these observations is that chemokine receptor processing and transport via the endoplasmic reticulum and Golgi apparatus may be disrupted, degraded, or downgraded by adenosine A 2A receptor stimulation. Adenosine A 2A receptor stimulation may also increase the rate at which CCR7 receptors are cleared from the surface of the cell, as previously demonstrated for other chemotactic receptors in neutrophils [25] [26] [27] . Alternatively, translation of CCR7 message may be blocked by adenosine receptor-stimulated microRNAs; a database search has found some miRNAs with sequence similarity of more than 65% with CCR7, although they are not located in the 5′ region considered most effective for translational blocking (mirbase.org) [28] [29] [30] [31] .
To determine a signal transduction pathway between A 2A adenosine receptor activation and CCR7 expression, we tested pharmacologic signal transduction inhibitors corresponding to previously demonstrated adenosine A 2A receptor signaling pathways. A 2A adenosine receptor stimulation can activate either the signaling proteins Epac or PKA [17, 32, 33] . PKA activation may then influence many possible downstream pathways, most commonly Erk with its upstream protein Mek and p38 with its upstream protein Rac [21, 34, 35] . We found PKA inhibition reversed A 2A adenosine receptorinduced changes in CCR7 message, while Epac analog treatment failed to mimic expression, indicating a PKAdependent pathway. Mek inhibition blocked change in CCR7 expression as well, while p38 and Rac inhibition did not affect CCR7 message but did change CCR7 protein expression. These results suggest A 2A adenosine receptor activation in THP1 macrophages leads to MAPK signaling through a PKA-dependent pathway for CCR7 expression.
Although we showed the presence of IFNγ did not hinder A 2A adenosine receptor's ability to reduce CCR7 expression and cell migration, the cytokines TNFα and interleukin-1 also affect A 2A adenosine receptor expression but were not examined [13] . A thorough examination of the other two cytokines with CGS21680, or a possible combination of all three, would give a better understanding of the receptor's function in an inflammatory, atherogenic environment.
An increasing body of literature demonstrates that adenosine and its receptors may play a role in the development and regression of atherosclerosis. Prior work demonstrates that adenosine A 2A receptor activation diminishes foam cell formation not only by increasing ABCA1 expression but by increasing its function as well [12, [36] [37] [38] [39] . We now provide further evidence that adenosine and its receptors might play a beneficial role in atherosclerosis by inhibiting recruitment of macrophages to atherosclerotic plaques. Fig. 6 . The A 2A adenosine receptor uses signaling pathways downstream of PKA to regulate CCR7 expression. The A 2A adenosine receptor subtype's G-stimulatory protein subunit (G s ) activates adenylate cyclase (AC), which leads to production of cAMP and stimulation of primarily p38 signaling to decrease CCR7 protein and primarily MA-PK signaling to increase CCR7 mRNA in THP1 macrophages.
